echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO Open: Are older cancer patients at higher risk of side effects from immunosuppressant treatment?

    ESMO Open: Are older cancer patients at higher risk of side effects from immunosuppressant treatment?

    • Last Update: 2021-02-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cancer is a disease that affects the elderly and is estimated to account for 55 per cent of new confirmed cancer cases.
    , older cancer patients are heterogeneic and the risk-benefit assessment of specific treatment strategies is difficult.
    , older cancer patients are underrepresented in clinical trials of many important therapeutic drugs, such as checkpoint inhibitors (CPIs).
    LDERS study aims to investigate the effects of the aging immune system on CPI-related toxicity and to provide evidence of the role of CPI in the assessment of old age.
    LDERS study is a forward-looking observational study that includes two cohorts: the elderly (over 70 years old) and the young (under 70 years of age).
    patients with advanced/metastasis non-small cell lung cancer or melanoma treated with single-drug CPI.
    used Geriatric-8 (G8) to screen patients in the elderly queue, followed by a comprehensive assessment of the elderly when the screening was positive.
    endpoints are the occurrence of level 3-5 immune-related adverse events (irAEs).
    140 patients were admitted to the group, of whom 43% were pretreated and Pim monoantigen accounted for 92% of the study treatment.
    the elderly queue had a higher combined burden (P.lt;0.001) and a multidrample co-use burden (P-0.004).
    50 per cent positive for G8 screening in older patients, while 60 per cent of patients in this vulnerable subgroup had a performance status score of only 0-1.
    difference in the occurrence of 3-5 irAEs in the old and young queues was not statistically significant (18.6% vs. 12.9%; advantage ratio was 1.55, 95% CI 0.61-3.89; P=0.353).
    older patients were treated with systemic steroids for irAE (22 weeks vs 8 weeks; P=0.208).
    the risk of hospitalization (P=0.031) and death (P=0.01) for patients who are positive for G8 screening.
    in short, older cancer patients do not have any higher adverse reactions to CPI treatment than younger people.
    G8 screening identified a sub-group with a higher AE risk, and G8 screening of patients should be considered in the context of CPI treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.